Metsera Secures $215M in Series B Funding to Advance Obesity and Metabolic Disease Portfolio

New York, November 13, 2024 (Business Wire) -- Metsera has raised $215 million in Series B financing, led by Wellington Management and Venrock. The company is focused on advancing its portfolio of clinical-stage peptides, including trials for its GLP-1 RA and amylin analog therapies. With over $500 million in total funding, Metsera is accelerating efforts to address obesity and metabolic diseases.

Read full article here.